YS vs. AVIR, QTTB, KMDA, XOMA, EPIX, EBS, INZY, VNDA, RVNC, and CRMD
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include Atea Pharmaceuticals (AVIR), Q32 Bio (QTTB), Kamada (KMDA), XOMA (XOMA), ESSA Pharma (EPIX), Emergent BioSolutions (EBS), Inozyme Pharma (INZY), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), and CorMedix (CRMD). These companies are all part of the "pharmaceutical preparations" industry.
Atea Pharmaceuticals (NASDAQ:AVIR) and YS Biopharma (NASDAQ:YS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
Atea Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
In the previous week, YS Biopharma had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for YS Biopharma and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.42 beat YS Biopharma's score of 0.94 indicating that YS Biopharma is being referred to more favorably in the news media.
Atea Pharmaceuticals received 16 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
YS Biopharma has a consensus target price of $5.25, indicating a potential upside of 528.74%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe YS Biopharma is more favorable than Atea Pharmaceuticals.
YS Biopharma has higher revenue and earnings than Atea Pharmaceuticals.
Atea Pharmaceuticals' return on equity of 0.00% beat YS Biopharma's return on equity.
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 52.6% of YS Biopharma shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
YS Biopharma beats Atea Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
